Wave Life Sciences Ltd. (WVE) announced Monday it's taking back full ownership of WVE-006 from GSK Plc (GSK), a move that clears the way for faster regulatory conversations and a potentially quicker path to market.

Here's the logic: GSK's respiratory business is built for blockbuster diseases that affect millions of people. WVE-006, meanwhile, targets alpha-1 antitrypsin deficiency, or AATD, which is decidedly not a mass-market opportunity. Both companies agreed Wave is better suited to shepherd this rare disease program forward, so they're amicably parting ways on this particular asset.

AATD is a genetic disorder caused by mutations in the SERPINA1 gene. Patients end up with dangerously low levels of alpha-1 antitrypsin, a protective protein that normally shields the lungs and liver from damage. Without enough of it, people develop severe emphysema, COPD, and liver disease, often at a young age.

The handoff happened before the next batch of clinical data arrives, which is notable timing. Wave's RestorAATion-2 trial is still chugging along on schedule, with results from the 400 mg multidose cohort expected in the first quarter of 2026. After that, data from the final 600 mg cohort, both single and multidose, should land sometime later in 2026.

Now that Wave has full control, the company is wasting no time. It's accelerating its regulatory game plan and intends to sit down with the FDA to discuss an accelerated approval pathway. The company expects to hear back from regulators around mid-2026, which would be a meaningful milestone if the science cooperates.

The GSK relationship isn't over, though. The two companies are still collaborating on other programs using Wave's PRISM platform technology. In fact, GSK just selected a fourth program to advance to development candidate status in January 2026. Under their agreement, GSK can move forward with up to eight programs total. If all of them progress through development, Wave stands to collect up to $2.8 billion in milestone payments. That's the kind of partnership that keeps the lights on and then some.

Speaking of which, Wave says its current cash reserves should fund operations into the third quarter of 2028, giving the company a comfortable runway as these programs mature.

Price Action: WVE stock climbed 4.48% to $13.52 on Monday.